A carregar...
Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study
A primary analysis of the ASPIRE study found that the addition of carfilzomib to lenalidomide and dexamethasone (carfilzomib group) significantly improved progression‐free survival (PFS) compared with lenalidomide and dexamethasone alone (control group) in patients with relapsed multiple myeloma (RM...
Na minha lista:
| Publicado no: | Br J Haematol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5412871/ https://ncbi.nlm.nih.gov/pubmed/28211560 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.14549 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|